治疗方案-话题@MedSci

#治疗方案#

313篇内容 | 2573人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1905214, encodeId=7ba9190521451, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=生物制剂治疗方案的安全管理：治疗前筛查与治疗后监测, objectType=article, longId=734589, objectId=7cfee34589f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cfee34589f8, replyNumber=0, likeNumber=62, createdTime=2023-01-11, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cfee34589f8, moduleTitle=生物制剂治疗方案的安全管理：治疗前筛查与治疗后监测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cfee34589f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905210, encodeId=e6c419052100b, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=二联口服降糖治疗方案, objectType=article, longId=733608, objectId=22eee33608cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22eee33608cc, replyNumber=0, likeNumber=73, createdTime=2023-04-14, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22eee33608cc, moduleTitle=二联口服降糖治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22eee33608cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905204, encodeId=82e21905204f9, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=各实体瘤已上市的靶向及免疫治疗方案大盘点！, objectType=article, longId=723854, objectId=a691e2385469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a691e2385469, replyNumber=0, likeNumber=72, createdTime=2022-11-22, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a691e2385469, moduleTitle=各实体瘤已上市的靶向及免疫治疗方案大盘点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a691e2385469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905213, encodeId=b566190521333, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=NCCN肝癌治疗临床指南前沿方案调整解析！新治疗方案生存率如何？, objectType=article, longId=731879, objectId=ad8de31879a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad8de31879a3, replyNumber=0, likeNumber=66, createdTime=2023-03-29, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad8de31879a3, moduleTitle=NCCN肝癌治疗临床指南前沿方案调整解析！新治疗方案生存率如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad8de31879a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905215, encodeId=c7e019052156d, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=IMpower010研究生存数据首次公布，夯实阿替利珠单抗为标准辅助治疗方案！| WCLC 2022速递, objectType=article, longId=735782, objectId=d1d6e3578230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1d6e3578230, replyNumber=0, likeNumber=81, createdTime=2023-06-16, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1d6e3578230, moduleTitle=IMpower010研究生存数据首次公布，夯实阿替利珠单抗为标准辅助治疗方案！| WCLC 2022速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1d6e3578230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905201, encodeId=5bc61905201d6, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=NCC：DCI的升压和正性肌力治疗方案, objectType=article, longId=301855, objectId=73e13018552d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73e13018552d, replyNumber=0, likeNumber=71, createdTime=2022-09-17, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73e13018552d, moduleTitle=NCC：DCI的升压和正性肌力治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73e13018552d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905208, encodeId=9ac11905208d1, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Nature：对先天性心脏病进展的新认识为改善治疗方案打开了大门, objectType=article, longId=730860, objectId=6aa5e308602d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aa5e308602d, replyNumber=0, likeNumber=67, createdTime=2023-04-15, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aa5e308602d, moduleTitle=Nature：对先天性心脏病进展的新认识为改善治疗方案打开了大门, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aa5e308602d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905219, encodeId=ae5e19052193e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=生物制剂DMARDs治疗方案的常见临床问题, objectType=article, longId=738089, objectId=f912e3808982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f912e3808982, replyNumber=0, likeNumber=78, createdTime=2023-06-09, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f912e3808982, moduleTitle=生物制剂DMARDs治疗方案的常见临床问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f912e3808982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905194, encodeId=7ffe190519455, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=BMC Cancer：白蛋白紫杉醇联合PD-1抑制剂信迪利单抗是晚期软组织肉瘤(STS)的有前景治疗方案, objectType=article, longId=294052, objectId=a3fb294052fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3fb294052fd, replyNumber=0, likeNumber=78, createdTime=2022-06-28, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3fb294052fd, moduleTitle=BMC Cancer：白蛋白紫杉醇联合PD-1抑制剂信迪利单抗是晚期软组织肉瘤(STS)的有前景治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3fb294052fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905211, encodeId=e30e190521152, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Dermatol Ther：阿普斯特单药治疗是中重度斑块状银屑病的有效治疗方案, objectType=article, longId=733991, objectId=cffee33991ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cffee33991ac, replyNumber=0, likeNumber=66, createdTime=2022-08-28, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cffee33991ac, moduleTitle=Dermatol Ther：阿普斯特单药治疗是中重度斑块状银屑病的有效治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cffee33991ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905216, encodeId=ef5119052160e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=世界前沿治疗方案触手可及 | 困在“首刀失败”困境里的脑瘤患者们：如何在INC重获新生？, objectType=article, longId=735565, objectId=de4ce3556575, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de4ce3556575, replyNumber=0, likeNumber=78, createdTime=2023-02-14, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de4ce3556575, moduleTitle=世界前沿治疗方案触手可及 | 困在“首刀失败”困境里的脑瘤患者们：如何在INC重获新生？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de4ce3556575)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905196, encodeId=17fd190519623, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Clin Cancer Res：局部晚期直肠癌的新治疗方案——术前放化疗联合纳武单抗巩固继以根治性手术！, objectType=article, longId=295321, objectId=eb062953218f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb062953218f, replyNumber=0, likeNumber=62, createdTime=2022-05-30, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb062953218f, moduleTitle=Clin Cancer Res：局部晚期直肠癌的新治疗方案——术前放化疗联合纳武单抗巩固继以根治性手术！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb062953218f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905218, encodeId=bb311905218cd, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=一文速览：乳腺癌常用药物及治疗方案大盘点, objectType=article, longId=737211, objectId=5b7ee37211e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b7ee37211e8, replyNumber=0, likeNumber=58, createdTime=2022-09-26, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b7ee37211e8, moduleTitle=一文速览：乳腺癌常用药物及治疗方案大盘点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b7ee37211e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905217, encodeId=72a6190521e4d, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=小细胞肺癌，国内外治疗方案大比拼（2022.2版）, objectType=article, longId=729295, objectId=7ef2e292953d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ef2e292953d, replyNumber=0, likeNumber=54, createdTime=2022-09-30, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ef2e292953d, moduleTitle=小细胞肺癌，国内外治疗方案大比拼（2022.2版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ef2e292953d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905198, encodeId=75b41905198d5, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Ther Adv Med Oncol：北京协和医院团队真实世界探索HER2改变的晚期NSCLC患者更佳一线治疗方案, objectType=article, longId=300517, objectId=5c7c30051ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c7c30051ed6, replyNumber=0, likeNumber=64, createdTime=2023-01-29, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c7c30051ed6, moduleTitle=Ther Adv Med Oncol：北京协和医院团队真实世界探索HER2改变的晚期NSCLC患者更佳一线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c7c30051ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905197, encodeId=b975190519eaf, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Rheumatology：FREE-J研究中类风湿关节炎缓解期患者基于共同决策的治疗方案选择, objectType=article, longId=299675, objectId=82992996e5c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82992996e5c3, replyNumber=0, likeNumber=99, createdTime=2022-08-06, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82992996e5c3, moduleTitle=Rheumatology：FREE-J研究中类风湿关节炎缓解期患者基于共同决策的治疗方案选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82992996e5c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2092792, encodeId=8fc02092e9244, content=<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a><a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a><a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a>，现在主要看<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>和<a href='/topic/show?id=c31310491053' target=_blank style='color:#2F92EE;'>#鲁比卡丁#</a>这一类新药，虽然整体疗效仍然不理想。, objectTitle=小细胞肺癌，国内外治疗方案大比拼（2022.2版）, objectType=article, longId=729295, objectId=7ef2e292953d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201230/1609342591541_2020535.jpg, objectUrl=/article/show_article.do?id=7ef2e292953d, replyNumber=0, likeNumber=139, createdTime=2022-10-10, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ef2e292953d, moduleTitle=小细胞肺癌，国内外治疗方案大比拼（2022.2版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ef2e292953d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905183, encodeId=eb66190518308, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Aesthetic Plast Surg ：隆胸患者植入物相关感染的治疗方案选择, objectType=article, longId=218394, objectId=5a1a218394cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a1a218394cf, replyNumber=0, likeNumber=78, createdTime=2021-11-30, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a1a218394cf, moduleTitle=Aesthetic Plast Surg ：隆胸患者植入物相关感染的治疗方案选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a1a218394cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905203, encodeId=d0c9190520376, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Cancer：ER阳性低表达（IHC 1%-10%）乳腺癌患者短程（2-3年）辅助内分泌治疗是可选择的治疗方案, objectType=article, longId=723583, objectId=9000e235839c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9000e235839c, replyNumber=0, likeNumber=68, createdTime=2022-06-03, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9000e235839c, moduleTitle=Cancer：ER阳性低表达（IHC 1%-10%）乳腺癌患者短程（2-3年）辅助内分泌治疗是可选择的治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9000e235839c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905207, encodeId=a789190520e83, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=NEJM：循环肿瘤DNA分析用于II期结肠癌患者术后治疗方案决策, objectType=article, longId=729745, objectId=43d8e29745b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43d8e29745b7, replyNumber=0, likeNumber=75, createdTime=2023-03-01, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43d8e29745b7, moduleTitle=NEJM：循环肿瘤DNA分析用于II期结肠癌患者术后治疗方案决策, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43d8e29745b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

生物制剂治疗方案的安全管理：治疗前筛查与治疗后监测

2023-01-11

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

二联口服降糖治疗方案

2023-04-14

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

各实体瘤已上市的靶向及免疫治疗方案大盘点！

2022-11-22

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

NCCN肝癌治疗临床指南前沿方案调整解析！新治疗方案生存率如何？

2023-03-29

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

IMpower010研究生存数据首次公布，夯实阿替利珠单抗为标准辅助治疗方案！| WCLC 2022速递

2023-06-16

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

NCC：DCI的升压和正性肌力治疗方案

2022-09-17

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Nature：对先天性心脏病进展的新认识为改善治疗方案打开了大门

2023-04-15

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

生物制剂DMARDs治疗方案的常见临床问题

2023-06-09

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

BMC Cancer：白蛋白紫杉醇联合PD-1抑制剂信迪利单抗是晚期软组织肉瘤(STS)的有前景治疗方案

2022-06-28

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Dermatol Ther：阿普斯特单药治疗是中重度斑块状银屑病的有效治疗方案

2022-08-28

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

世界前沿治疗方案触手可及 | 困在“首刀失败”困境里的脑瘤患者们：如何在INC重获新生？

2023-02-14

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Clin Cancer Res：局部晚期直肠癌的新治疗方案——术前放化疗联合纳武单抗巩固继以根治性手术！

2022-05-30

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

一文速览：乳腺癌常用药物及治疗方案大盘点

2022-09-26

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

小细胞肺癌，国内外治疗方案大比拼（2022.2版）

2022-09-30

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Ther Adv Med Oncol：北京协和医院团队真实世界探索HER2改变的晚期NSCLC患者更佳一线治疗方案

2023-01-29

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Rheumatology：FREE-J研究中类风湿关节炎缓解期患者基于共同决策的治疗方案选择

2022-08-06

lifestar (审核中...)

前往app查看评论内容

#小细胞肺癌##治疗方案##肺癌#，现在主要看#免疫治疗#和#鲁比卡丁#这一类新药，虽然整体疗效仍然不理想。

小细胞肺癌，国内外治疗方案大比拼（2022.2版）

2022-10-10

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Aesthetic Plast Surg ：隆胸患者植入物相关感染的治疗方案选择

2021-11-30

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Cancer：ER阳性低表达（IHC 1%-10%）乳腺癌患者短程（2-3年）辅助内分泌治疗是可选择的治疗方案

2022-06-03

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

NEJM：循环肿瘤DNA分析用于II期结肠癌患者术后治疗方案决策

2023-03-01

科室
- - 订阅+
  - 更多科室
工具
服务